Transpulmonary pressure in SARS-CoV-2-associated acute respiratory distress syndrome: a single-center observational study
Critical Care volume 24, Article number: 408 (2020)
Gattinoni et al.  have recently described that the ARDS related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was not a “typical” ARDS. Patients indeed presented a significant hypoxemia, which was surprisingly associated with a high compliance of the respiratory system. The cornerstone of current treatment is the use of “lung protective” ventilation strategy with especially maintaining sufficiently high positive end-expiratory pressures (PEEP). However, high levels of PEEP may lead to lung overdistension associated with an increase of alveolar dead space and an alteration of gas exchanges. The airway pressures commonly monitored on respirators do not reliably reflect the impact of pressures on the lung parenchyma. In contrast, transpulmonary pressures allow to highlight directly lung overdistension risk and lung properties. In order to better know this new kind of ARDS, transpulmonary pressures’ assessment seems to be essential .
We wish to report the preliminary findings of a prospective monocentric physiological work, which is approved by the institutional ethics review board of the Montpellier University Hospital, France (IRB ID: 202000432). All consecutive ARDS adult patients with confirmed Covid-19 admitted in our critical care unit are included if they received invasive mechanical. Management of patients followed international recommendations. PEEP was set according to the low PEEP arm of the PEEP/FiO2 table used in previous trials. Esophageal pressures were recorded with Cooper Surgical® device.
Sixteen patients were assessed (body mass index 29 [range 26–31] kg/m2, age 70 years [range 61–72 years]). The median worst value of PaO2/FiO2 ratio was 144 mmHg [range 138–149 mmHg]. Baseline of patient characteristics may be observed in the Table 1. Six patients received at least one session of prone positioning. One of them also benefited from VV-ECMO. We observed that median transpulmonary end-expiratory pressure was positive during mechanical ventilation (2 cm H2O at D1 [range − 1–3 cm H2O]) and median transpulmonary elastance (EL) remained low at day 1 (19 cm H2O/L [range 8–20 cm H2O/L]) and during the first week. All our findings are shown in Fig. 1.
Many reports have highlighted specificities of SARS-CoV-2, particularly that the elastance of respiratory system (ERS) was slightly altered. Driving pressures of the respiratory system are therefore quite low in these patients. Unsurprisingly, our study showed that the EL was not elevated in the first days of mechanical ventilation. The main finding of the present work is that end-expiratory transpulmonary pressure remained positive in most patients with the use of moderate PEEP (8–13 cm H2O). To summarize, our analysis is in agreement with the descriptions of Gattinoni et al. . Most of these patients present indeed low ERS, low ventilation to perfusion ratio (VA/Q), and low lung recruitability due to the low amount of non-aerated tissue (L profile). Hypoxemia and intrapulmonary shunt might thus be better explained by dysregulation of pulmonary perfusion and by alteration of hypoxic vasoconstriction. This would justify the use of moderate levels of PEEP to limit alveolar dead space and optimize the CO2 removal. Gattinoni et al.  also described that 20–30% of patients presented a delayed aggravation with more usual pulmonary parameters: high ERS, high right-to-left shunt, high lung recruitability (H profile). Constitution of atelectasis or bacterial overinfection is associated with H profile. This is observable in our series since a part of patients experienced an increase of ERS as EL (Fig. 1c). For the latter, elevated PEEP seems to be more legitimate . To conclude, identification of respiratory phenotype seems therefore essential in ventilated SARS-CoV-2 patients to determine optimal mechanical ventilation strategy. Our observations support the concept of using low PEEP in a large part of SARS-CoV-2 patients.
Availability of data and materials
Gattinoni L, Coppola S, Cressoni M, Busana M, Chiumello D. Covid-19 does not lead to a “typical” acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020;201(10):1299–300.
Gattinoni L, Giosa L, Bonifazi M, Pasticci I, Busana M, Macri M, et al. Targeting transpulmonary pressure to prevent ventilator-induced lung injury. Expert Rev Respir Med. 2019;13(8):737–46.
Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020;46(6):1099–102.
Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care Lond Engl. 2020;24(1):154.
Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020;323(22):2329–30.
No finding received.
Ethics approval and consent to participate
Institutional ethics review board of the Montpellier University Hospital, France (IRB ID: 202000432).
Consent for publication
No competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ramin, S., Charbit, J., Dagod, G. et al. Transpulmonary pressure in SARS-CoV-2-associated acute respiratory distress syndrome: a single-center observational study. Crit Care 24, 408 (2020). https://doi.org/10.1186/s13054-020-03129-5